No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 327.4x · 10Y median 68.4x · 78th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:51.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Anteris Technologies Global Corp. (AVR) stock was $7.55 as of Oct 5, 2026, 4:00 PM EDT, down 2.08% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +74.7%
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis.
Medical - Devices · Eagan, MN
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.31
Revenue Est.
$2.75M
Last Quarter Results
EPS
$-0.30
vs Estimate
$-0.21
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AVR | $734.10M | $7.55 | -2.08% | +74.71% | N/A | N/A | N/A |
| 2ACHV | $719.64M | $7.01 | -3.18% | +121.94% | -4.33% | -39.18% | vs AVR |
| 3CADL | $749.55M | $10.23 | +0.49% | +83.46% | -1.42% | N/A | vs AVR |
| 4COLL | $709.33M | $21.87 | -0.68% | -36.67% | +2.15% | +1.39% | vs AVR |
| 5HELP | $707.86M | $11.42 | -2.39% | N/A | N/A | N/A | vs AVR |
| 6AVTX | $767.46M | $14.60 | -2.60% | +8.91% | -70.04% | -48.70% | vs AVR |
forward FY estimate
N/A
$1.01M
vs Estimate
$1.50M
Consensus Rating
Based on 3 analysts
Average Price Target
$15.33
+103.1% upside
Low
$15.00
Current
$7.55
High
$16.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.32 | $-0.31 | $-0.30 | 3 |
| Quarter ending Dec 2026 | $-0.32 | $-0.30 | $-0.29 | 3 |
| Quarter ending Mar 2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Quarter ending Jun 2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.24 | $-1.23 | $-1.21 | 2 |
| FY 2027 | $-1.34 | $-1.13 | $-0.91 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $397598.00 | $2.75M | $4.80M | 4 |
| Quarter ending Dec 2026 | $2.95M | $2.95M | $2.95M | 4 |
| Quarter ending Mar 2027 | $2.60M | $2.60M | $2.60M | 2 |
| Quarter ending Jun 2027 | $2.60M | $2.60M | $2.60M | 2 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.90M | $7.17M | $12.18M | 3 |
| FY 2027 | $9.86M | $10.00M | $10.14M | 3 |
